JP2015526467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526467A5 JP2015526467A5 JP2015528536A JP2015528536A JP2015526467A5 JP 2015526467 A5 JP2015526467 A5 JP 2015526467A5 JP 2015528536 A JP2015528536 A JP 2015528536A JP 2015528536 A JP2015528536 A JP 2015528536A JP 2015526467 A5 JP2015526467 A5 JP 2015526467A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- liposomes
- liposome
- eye
- ophthalmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 150000003431 steroids Chemical group 0.000 claims 7
- 239000000725 suspension Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 3
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000002137 anti-vascular effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 229940100654 ophthalmic suspension Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691455P | 2012-08-21 | 2012-08-21 | |
| US61/691,455 | 2012-08-21 | ||
| US201361791693P | 2013-03-15 | 2013-03-15 | |
| US61/791,693 | 2013-03-15 | ||
| US201361862300P | 2013-08-05 | 2013-08-05 | |
| US61/862,300 | 2013-08-05 | ||
| PCT/US2013/055084 WO2014031429A2 (en) | 2012-08-21 | 2013-08-15 | Liposome formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088574A Division JP6680827B2 (ja) | 2012-08-21 | 2018-05-02 | リポソーム製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526467A JP2015526467A (ja) | 2015-09-10 |
| JP2015526467A5 true JP2015526467A5 (enExample) | 2016-10-06 |
| JP6336448B2 JP6336448B2 (ja) | 2018-06-06 |
Family
ID=50150466
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528536A Active JP6336448B2 (ja) | 2012-08-21 | 2013-08-15 | リポソーム製剤 |
| JP2018088574A Active JP6680827B2 (ja) | 2012-08-21 | 2018-05-02 | リポソーム製剤 |
| JP2020046303A Active JP7098674B2 (ja) | 2012-08-21 | 2020-03-17 | リポソーム製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088574A Active JP6680827B2 (ja) | 2012-08-21 | 2018-05-02 | リポソーム製剤 |
| JP2020046303A Active JP7098674B2 (ja) | 2012-08-21 | 2020-03-17 | リポソーム製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10548841B2 (enExample) |
| EP (1) | EP2887958B1 (enExample) |
| JP (3) | JP6336448B2 (enExample) |
| KR (2) | KR102083700B1 (enExample) |
| CN (1) | CN104582728A (enExample) |
| AR (1) | AR092372A1 (enExample) |
| BR (1) | BR112015003658B1 (enExample) |
| CA (2) | CA2879597C (enExample) |
| CL (1) | CL2015000418A1 (enExample) |
| ES (1) | ES2881671T3 (enExample) |
| HU (1) | HUE058912T2 (enExample) |
| MX (2) | MX363822B (enExample) |
| PL (1) | PL2887958T3 (enExample) |
| RU (1) | RU2680096C2 (enExample) |
| TW (2) | TWI608848B (enExample) |
| WO (1) | WO2014031429A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016000282A2 (pt) * | 2013-07-11 | 2017-12-12 | Novartis Ag | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
| MX2016005505A (es) * | 2013-12-19 | 2016-07-22 | Hoffmann La Roche | Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares. |
| EP3145532A4 (en) * | 2014-05-02 | 2018-02-21 | Mayo Foundation for Medical Education and Research | Individualized treatment of eye disease |
| KR101778004B1 (ko) | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
| AR106690A1 (es) * | 2015-11-13 | 2018-02-07 | Ohr Pharmaceutical Inc | Método para administrar escualamina o una sal farmacéuticamente aceptable a la esclerótica posterior y a la coroides del ojo |
| WO2019154776A1 (en) * | 2018-02-06 | 2019-08-15 | F. Hoffmann-La Roche Ag | Treatment of ophthalmologic diseases |
| WO2020041689A1 (en) * | 2018-08-23 | 2020-02-27 | Bernstein Eric F | Systems, devices and methods for applying anti-vegf compounds and using such compounds to treat skin conditions |
| CN109180798B (zh) * | 2018-09-04 | 2020-10-27 | 武汉原生药谷生物医药科技有限公司 | 一种增强型治疗性抗体及其应用 |
| WO2020089051A1 (en) | 2018-10-29 | 2020-05-07 | F. Hoffmann-La Roche Ag | Antibody formulation |
| US20200323882A1 (en) * | 2019-03-15 | 2020-10-15 | University Of Rhode Island Board Of Trustees | Phlip®-mediated targeting of corticosteroids to diseased tissue |
| MX2021014000A (es) | 2019-05-16 | 2021-12-10 | Opko Pharmaceuticals Llc | Formulaciones oftalmicas topicas de liposomas cargados con acetonido de triamcinolona para la prevencion del engrosamiento macular y sus resultados visuales asociados despues de la cirugia del cristalino. |
| CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
| EP4164593A1 (en) * | 2020-06-15 | 2023-04-19 | OPKO Pharmaceuticals, LLC | Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion |
| CN116585304B (zh) * | 2023-04-25 | 2024-04-05 | 四川大学华西医院 | 一种急性肝损伤保护药物及其制备方法 |
| WO2025146683A1 (en) | 2024-01-03 | 2025-07-10 | Lyotropic Delivery Systems Ltd. | Topical formulations for delivery of an active compound to the back of the eye |
| CN119701010B (zh) * | 2024-12-25 | 2025-10-28 | 山东第一医科大学附属眼科医院(山东省眼科医院) | 一种基于中性粒细胞纳米囊泡的抗炎和抗血管双向诱捕联合自发光动力的复合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6565861B1 (en) * | 2000-02-11 | 2003-05-20 | Isis Innovation Limited | Artificial tear formulation |
| US6610322B1 (en) * | 2000-12-20 | 2003-08-26 | Brian Charles Keller | Self forming, thermodynamically stable liposomes and their applications |
| US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| US20060165744A1 (en) * | 2003-05-22 | 2006-07-27 | Neopharm, Inc | Combination liposomal formulations |
| WO2007076274A2 (en) * | 2005-12-22 | 2007-07-05 | Bausch & Lomb Incorporated | Artificial tear solution containing poly (ethylene glycol) peg lipids |
| WO2007076454A1 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| EP2089059A2 (en) * | 2006-11-10 | 2009-08-19 | Genentech, Inc. | Method for treating age-related macular degeneration |
| US7888352B2 (en) | 2006-12-07 | 2011-02-15 | Piramed Limited | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| JP2011500086A (ja) * | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | 完全ヒト抗ｖｅｇｆ抗体および使用方法 |
| US8887944B2 (en) * | 2007-12-11 | 2014-11-18 | Tokitae Llc | Temperature-stabilized storage systems configured for storage and stabilization of modular units |
| SG171952A1 (en) * | 2008-12-04 | 2011-07-28 | Opko Ophthalmics Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
| JP2012528857A (ja) | 2009-06-02 | 2012-11-15 | ウー，ニエン | 純粋ｐｅｇ−脂質コンジュゲート |
| US20110033527A1 (en) | 2009-06-02 | 2011-02-10 | Nian Wu | Opthalmic compositions of cyclosporin |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| KR20120063515A (ko) * | 2009-09-09 | 2012-06-15 | 아빌라 테라퓨틱스, 인크. | Ｐｉ３ 키나제 억제제 및 이들의 용도 |
-
2013
- 2013-08-15 BR BR112015003658-9A patent/BR112015003658B1/pt active IP Right Grant
- 2013-08-15 ES ES13830622T patent/ES2881671T3/es active Active
- 2013-08-15 CA CA2879597A patent/CA2879597C/en active Active
- 2013-08-15 HU HUE13830622A patent/HUE058912T2/hu unknown
- 2013-08-15 WO PCT/US2013/055084 patent/WO2014031429A2/en not_active Ceased
- 2013-08-15 CA CA3098856A patent/CA3098856C/en active Active
- 2013-08-15 US US14/422,587 patent/US10548841B2/en active Active
- 2013-08-15 CN CN201380044348.4A patent/CN104582728A/zh active Pending
- 2013-08-15 MX MX2015002233A patent/MX363822B/es active IP Right Grant
- 2013-08-15 EP EP13830622.0A patent/EP2887958B1/en active Active
- 2013-08-15 PL PL13830622T patent/PL2887958T3/pl unknown
- 2013-08-15 RU RU2015107317A patent/RU2680096C2/ru active
- 2013-08-15 JP JP2015528536A patent/JP6336448B2/ja active Active
- 2013-08-15 KR KR1020157004549A patent/KR102083700B1/ko active Active
- 2013-08-15 KR KR1020207005268A patent/KR102177437B1/ko active Active
- 2013-08-21 AR ARP130102960A patent/AR092372A1/es not_active Application Discontinuation
- 2013-08-22 TW TW102130093A patent/TWI608848B/zh active
- 2013-08-22 TW TW105114326A patent/TWI683675B/zh active
-
2015
- 2015-02-19 MX MX2019001021A patent/MX2019001021A/es unknown
- 2015-02-20 CL CL2015000418A patent/CL2015000418A1/es unknown
-
2018
- 2018-05-02 JP JP2018088574A patent/JP6680827B2/ja active Active
-
2019
- 2019-12-12 US US16/712,261 patent/US11712419B2/en active Active
-
2020
- 2020-03-17 JP JP2020046303A patent/JP7098674B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526467A5 (enExample) | ||
| JP7569336B2 (ja) | マイクロエマルション組成物 | |
| JP5441058B2 (ja) | 四級アンモニウム化合物を含む組成物 | |
| JP2010536797A5 (enExample) | ||
| US20190133930A1 (en) | Methods of Anesthetizing Nerve Tissue in the Trigeminal Nerve Pathway and Medical Uses Thereof | |
| ES2405779T3 (es) | Gotas oftálmicas con difluprednato para tratamiento del edema macular | |
| JP6348567B2 (ja) | マイクロエマルジョン局所送達プラットフォーム | |
| US10406203B2 (en) | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents | |
| AU2007336206A1 (en) | Process for manufacturing ophthalmic oil-in-water emulsions | |
| JP2019094356A (ja) | 眼科用水性組成物 | |
| JP2009538879A (ja) | 後眼部の疾患治療用のステロイドプロドラッグの使用 | |
| JP2016512562A5 (enExample) | ||
| Thakkar et al. | Updates in ocular antifungal pharmacotherapy: Formulation and clinical perspectives | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| JP2013537551A5 (enExample) | ||
| TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
| AU2014216273A1 (en) | Topical ocular analgesic agents | |
| Kiernan et al. | Topical drug delivery for posterior segment disease | |
| CN104703606B (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐在药物组合物中作为视神经网膜保护物使用 | |
| CN103126983B (zh) | 二氟泼尼酯晶型i制备的乳剂 | |
| WO2007038549B1 (en) | Treatment of inflammation and vascular abnormalities of the eye | |
| Arcinue et al. | Corticosteroids in uveitis | |
| CA2442296A1 (en) | Therapeutic agents for retinochoroidal disorders comprising steroids as active ingredients | |
| JPWO2021021646A5 (enExample) | ||
| RU2022100077A (ru) | Изоксазолиновые паразитицидные составы и способы лечения блефарита |